dipyridamole has been researched along with End Stage Liver Disease in 2 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
End Stage Liver Disease: Final stage of a liver disease when the liver failure is irreversible and LIVER TRANSPLANTATION is needed.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aljizeeri, A | 1 |
| Alali Alfaris, M | 1 |
| Ahmed, D | 1 |
| Farea, J | 1 |
| Elneama, A | 1 |
| Suliman, I | 1 |
| Alharthi, M | 1 |
| Ahmed, A | 1 |
| Alsaileek, A | 1 |
| Al-Mallah, M | 1 |
| Abele, JT | 1 |
| Raubenheimer, M | 1 |
| Bain, VG | 1 |
| Wandzilak, G | 1 |
| AlHulaimi, N | 1 |
| Coulden, R | 1 |
| deKemp, RA | 1 |
| Klein, R | 1 |
| Williams, RG | 1 |
| Warshawski, RS | 1 |
| Lalonde, LD | 1 |
2 other studies available for dipyridamole and End Stage Liver Disease
| Article | Year |
|---|---|
Are Patients With End-Stage Liver Disease Maximally Vasodilated?: Insights From Rubidium-82 PET Dilatory Perfusion.
Topics: Aged; Coronary Artery Disease; Dipyridamole; End Stage Liver Disease; Female; Humans; Male; Middle A | 2019 |
Quantitative blood flow evaluation of vasodilation-stress compared with dobutamine-stress in patients with end-stage liver disease using
Topics: Adult; Aged; Coronary Circulation; Dipyridamole; Dobutamine; End Stage Liver Disease; Female; Humans | 2020 |